EVOLUTION OF CHRONIC HEART FAILURE OVER THE PAST TWO DECADES: A COMPARATIVE LITERATURE REVIEW OF TREATMENT AND CLINICAL CHARACTERISTICS

Authors

  • Yuldasheva Feruza Master Student in Cardiology, Department of Faculty Therapy. Andijan state medical institute Author

Keywords:

Keywords: chronic heart failure; epidemiological trends; clinical phenotypes; pharmacological therapy; therapeutic advances; guideline-directed management

Abstract

Chronic heart failure (CHF) continues to be a major global health problem, accounting for substantial morbidity, mortality, and healthcare costs. Although considerable progress has been achieved in the prevention and treatment of cardiovascular diseases, the burden of CHF continues to rise. This trend is primarily driven by population aging, the growing prevalence of cardiovascular risk factors, and increased survival following acute cardiac events. Over the last two decades, significant developments have occurred in the understanding of heart failure, including changes in its epidemiology, clinical manifestations, diagnostic criteria, and therapeutic management.CHF is a multifactorial clinical syndrome that develops as a consequence of structural and functional abnormalities of the myocardium, leading to impaired ventricular filling and/or reduced cardiac output. As a result, the heart is unable to maintain sufficient circulation to meet the body's metabolic requirements.

References

1.Pagnesi, M.; Baldetti, L.; Aimo, A.; Inciardi, R.M.; Tomasoni, D.; Vizzardi, E.; Vergaro, G.; Emdin, M.; Lombardi, C.M. Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis. J. Clin. Med. 2022, 11, 348.

2.Beltrami, M.; Milli, M.; Dei, L.L.; Palazzuoli, A. The Treatment of Heart Failure in Patients with Chronic Kidney Disease: Doubts and New Developments from the Last ESC Guidelines. J. Clin. Med. 2022, 11, 2243.

3.Gioia, M.I.; Parisi, G.; Grande, D.; Albanese, M.; Alcidi, G.; Correale, M.; Brunetti, N.D.; Ciccone, M.M.; Iacoviello, M. Effects of Sacubitril/Valsartan on the Renal Resistance Index. J. Clin. Med. 2022, 11, 3683.

4.Masarone, D.; Kittleson, M.M.; Martucci, M.L.; Valente, F.; Gravino, R.; Verrengia, M.; Ammendola, E.; Contaldi, C.; Di Palma, V.; Caiazzo, A.; et al. Levosimendan as a “Bridge to Optimization” in Patients with Advanced Heart Failure with Reduced Ejection-A Single-Center Study. J. Clin. Med. 2022, 11, 4227.

5.Cammalleri, V.; Antonelli, G.; De Luca, V.M.; Carpenito, M.; Nusca, A.; Bono, M.C.; Mega, S.; Ussia, G.P.; Grigioni, F. Functional Mitral and Tricuspid Regurgitation across the Whole Spectrum of Left Ventricular Ejection Fraction: Recognizing the Elephant in the Room of Heart Failure. J. Clin. Med. 2023, 12, 3316.

Downloads

Published

2026-06-09